Sign in
Not yet recruitingPhase 3

The REFINE study

Key facts

Who runs it
Karolinska University Hospital
Where
Sweden6 sites in 1 countryChoose a country to see its sites
Status
Not yet recruiting
Phase
Phase 3
People taking part
30 people, planned
Started
30 Sept 2025
Expected to end
31 Dec 2030
Type of study
Interventional
Record updated
17 October 2025

Who can take part

Age
18 years to 64 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • The subject has given their written consent to participate in the trial
  • Autoimmune POI (FSH > 25 IU/L) including the presence of oligo/amenorrhea lasting at least 4 months, and elevated FSH levels (FSH > 25 IU/L) confirmed on two separate occasions, with measurements taken at least 4 weeks apart and Addison’s disease or ab positivity for 21-hydroxylase or other relevant autoantibodies (SCC, 17-OH, NALP5)
  • 18-38 years of age
  • Body mass index between 19-30
  • Willing to use effective non-hormonal contraceptive method (such as intra uterine device (IUD), sexual abstinence, male or female condom with or without spermicide, cap, diaphragm or sponge with spermicide) during the 18-month study period

Who cannot take part

  • Hormone replacement therapy within four weeks prior study entry
  • Concurrent treatment with other immunosuppressive drugs
  • Any vaccination within 4 weeks of infusion of study medication
  • Any condition or any circumstance that in the opinion of the investigator would make it unsafe to undergo treatment with rituximab or controlled ovarian hyperstimulation
  • Hypersensitivity to rituximab, any of the AxMPs, or any of the excipients (as detailed in the SmPC for the various IMPs)
  • Vaginal bleeding of unknown etiology
  • Active hepatitis B infection
  • Active thrombolic disorder (contraindicated for Ovirelle)
  • Moderate or severe impairment of kidney or liver function (contraindicated for Orgalutran)
  • Severe psychiatric disorder
  • Active, severe infection or JCV positivity
  • Severe cardiac disease
  • Cancer
  • Benign tumours of the hypothalamus, pituitary, or ovarian pathology
  • Pregnant or lactating women
  • Severe immunosuppression

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 64 years old?

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The primary objective of this trial is to investigate the efficacy of rituximab in enabling egg retrieval after controlled ovarian hyperstimulation in autoimmune POI 4 to 6 months after rituximab compared to placebo, as well as the whole group treated with rituximab at 4 to 6 and 12 months after the last treatment session compared to baseline.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Immunomodulatory therapy to restore ovarian function and improve fertility in women with autoimmune premature ovarian insufficiency – a double-blind, placebo-controlled, randomized study
Criteria questions
Built from 2025-522133-66-00, who can take part
Record updated
17 October 2025